Zavegepant for the acute treatment of migraine: look before leaping
Crossref DOI link: https://doi.org/10.1038/s41582-023-00803-4
Published Online: 2023-04-03
Published Print: 2023-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ashina, HÃ¥kan http://orcid.org/0000-0002-6268-727X
Tfelt-Hansen, Peer
Text and Data Mining valid from 2023-04-03
Version of Record valid from 2023-04-03
Article History
First Online: 3 April 2023
Competing interests
: H.A. reports personal fees from Teva, outside of the submitted work. P.T.-H. declares no competing interests.